Overview
Thymalin is a peptide bioregulator derived from bovine thymus gland extract, developed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology in the 1970s. It represents one of the earliest compounds in the Khavinson peptide bioregulation paradigm.
The thymus undergoes progressive involution after puberty, contributing to immunosenescence. Thymalin provides thymic peptide factors that support T-cell differentiation, maturation, and functional competence.
A landmark 15-year study by Khavinson demonstrated that thymalin combined with epithalon reduced mortality by ~50% in elderly patients. Thymalin has been used clinically in Russia for over four decades.
This guide examines thymalin's pharmacology, clinical evidence, and its position in immunogerontology.
Quick facts
- Mechanism
- Thymus-derived peptide bioregulator for immune restoration
- Primary use
- Immune Modulation & Anti-Aging
- Evidence
- moderate
- FDA
- Not approved
- Route
- Intramuscular injection
- Typical results
- Immune marker improvement within 5–10 days of standard treatment course
Chemical information
Thymalin (C₃₃H₅₄N₁₂O₁₅) is a bioregulator compound with a molecular weight of 858.9 g/mol. Its structural characteristics underpin its biological activity in bioregulation and peptide signaling.
How Thymalin works
Thymalin stimulates immature thymocyte maturation into functional CD4+ helper cells, CD8+ cytotoxic cells, and regulatory T-cells. It restores the CD4/CD8 ratio and enhances NK cell cytotoxicity.
Thymalin peptides interact with lymphocyte DNA, modulating gene expression for immune function including cytokine receptor upregulation (IL-2R, IL-7R) and T-helper polarization transcription factors (T-bet, GATA-3).
Beyond immune effects, thymalin modulates the neuroendocrine-immune interface, affecting melatonin secretion and adrenal stress responses through bidirectional thymus-neuroendocrine communication.
It upregulates antioxidant enzymes (SOD, catalase, glutathione peroxidase), reduces chromosomal aberrations, and may restore telomere length in elderly lymphocytes.
- T-cell maturation: Promotes CD4+ and CD8+ T-cell differentiation
- CD4/CD8 restoration: Normalizes helper/cytotoxic ratio
- NK cell enhancement: Increases natural killer cell cytotoxicity
- Epigenetic modulation: Regulates immune gene expression
- Neuroendocrine crosstalk: Modulates HPA and pineal function
- Antioxidant upregulation: Enhances SOD and catalase activity
Pharmacokinetics
| Parameter | Value | Significance |
|---|---|---|
| Bioavailability | Rapid IM absorption | Courses repeated every 3–6 months |
| Onset of Action | Immune markers change within 3–5 days | Time to measurable clinical/biological response |
| Half-life | Minutes to hours (peptides); immunological effects persist weeks-months | Determines dosing frequency |
| Duration of Effect | Standard: 5–10 mg IM daily for 5–10 days; effects persist 3–6 months | Functional activity beyond plasma clearance |
| Metabolism | Proteolytic degradation | Primary elimination pathway |
Dosing & administration
Thymalin dosing varies by indication and individual factors. No FDA-approved dosing exists for this compound; protocols in the literature derive from limited clinical or preclinical data and practitioner experience.
Any use should be conducted under qualified medical supervision with appropriate monitoring of safety markers.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Safety data for Thymalin is primarily derived from preclinical studies and limited human data. Long-term effects in humans remain incompletely characterized.
Common
- • Injection site pain
- • Mild allergic reactions
- • Transient low-grade fever
- • Mild fatigue initially
- • Rare nausea/headache
Serious / potential risks
- • Allergic reaction to bovine material (rare)
- • Theoretical autoimmune flare risk
- • Contraindicated in active autoimmune disease
- • Limited Western clinical data
- • Unknown long-term effects of chronic immune stimulation
Drug interactions
| Medication | Interaction | Recommendation |
|---|---|---|
| Immunosuppressants | Opposing mechanisms | Avoid combination or use with extreme caution under medical supervision |
| Chronic corticosteroids | Accelerate thymic involution; may reduce efficacy | Monitor closely; dose adjustment may be required |
| Checkpoint inhibitors | Additive immune stimulation may increase autoimmune risk | Monitor closely; dose adjustment may be required |
| Vaccines | May enhance vaccine response | Generally safe; monitor if concerns arise |
Storage & handling
Lyophilized Powder for Injection
- • Refrigerate at 2–8°C
- • Protect from light
- • Reconstitute with 1–2 mL sterile saline
- • Use immediately after reconstitution
Reconstituted Solution
- • Use within 1 hour
- • Do not store
- • Administer IM
- • Standard: 5–10 mg daily for 5–10 days
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research suppliers | Varies widely | Quality and purity vary significantly between sources |
| Compounding pharmacies | Prescription required | Higher quality assurance and purity testing |
The bottom line
Thymalin is a bioregulator compound with research interest in immune modulation, thymus, anti-aging, bioregulation. While preclinical evidence is encouraging, it remains investigational and is not FDA-approved. Any use should be under qualified medical supervision.
Best for
- • Researchers studying bioregulation and peptide signaling
- • Individuals interested in immune modulation under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
Frequently asked questions
References
- [1] Khavinson VKh, Morozov VG.. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett (2003). PMID: 14523363
- [2] Kuznik BI, Linkova NS, Khavinson VKh.. Peptide bioregulators: a new class of geroprotectors. Adv Gerontol (2013). PMID: 25051755
- [3] Anisimov VN, Khavinson VKh.. Peptide bioregulation of aging: results and prospects. Biogerontology (2010). doi: 10.1007/s10522-009-9249-8 PMID: 19830585
- [4] Morozov VG, Khavinson VKh.. Natural and synthetic thymic peptides as therapeutics. Int J Immunopharmacol (1997). PMID: 9568540